This distribution is highly suggestive of a gain-of-function or dominant-negative mechanism, as has been observed in numerous other rare genetic disorders across many phenotypes,1,2,3 and has motivated a clinical trial to inhibit GAT-1 in schizophrenia.4 Here, SLC6A1 is linked to schizophrenia.